350 руб
Журнал «Технологии живых систем» №1 за 2013 г.
Статья в номере:
Перспективы создания противоопухолевых лекарственных средств, направленных на систему активатора плазминогена урокиназного типа
Ключевые слова: урокиназа рецептор урокиназы раковые новообразо-вания терапия ингибиторы урокиназы
Авторы:
И.Б. Белоглазова - к.б.н., науч. сотрудник, НИИ экспериментальной кардиологии ФГБУ «Российский кардиологический научно-производственный комплекс» Министерства здравоохранения и социального развития РФ. E-mail: irene.beloglazova@gmail.com Ж.А. Акопян - к.м.н., ученый секретарь, факультет фундаментальной медицины, МГУ им. М.В. Ломоносова. E-mail: hanna@fbm.msu.ru М.Н. Карагяур - лаборант-исследователь, НИИ экспериментальной кардиологии ФГБУ «Российский кардиологический научно-производственный комплекс» Министерства здравоохранения и социального развития РФ. E-mail: darth_max@mail.ru О.С. Плеханова - ст. науч. сотрудник, к.м.н., НИИ экспериментальной кардиологии ФГБУ «Российский кардиологический научно-производственный комплекс» Министерства здравоохранения и социального развития РФ. E-mail: plekhanova@mail.ru Е.В. Семина - к.б.н., науч. сотрудник, НИИ экспериментальной кардиологии ФГБУ «Российский кардиологический научно-производственный комплекс» Министерства здравоохранения и социального развития РФ. E-mail: e-tal@yandex.ru Д.В. Стамбольский - к.б.н., вед. науч. сотрудник, факультет фундаментальной медицины, МГУ им. М.В. Ломоносова; ст. науч. сотрудник, НИИ экспериментальной кардиологии ФГБУ «Российский кардиологический научно-производственный комплекс» Министерства здравоохранения и социального развития РФ. E-mail: dstambolsky@gmail.com
Аннотация:
Обсуждаются перспективы создания лекарственных средств имеющих своей мишенью урокиназную систему для подавления опухолевого ангиогенеза
Страницы: 3-19
Список источников
  1. Duffy M.J. The Urokinase Plasminogen Activator System: Role in Malignancy // Curr. Pharm. Des. 2004. V.10. P.39-49.
  2. Choong P.F., Nadesapillai A.P. Urokinase Plasminogen Activator System: A Multifunctional Role in Tumor Progression and Metastasis // Clin. Orthop. Relat. Res. 2003. V.415S. P.46-58.
  3. Ulisse S., Baldini E., Toller M., Marchioni E., Giacomelli L., De Antoni E., Ferretti E., Marzullo A., Graziano F.M., Trimboli P., Biordi L., Curcio F., Gulino A., Ambesi-Impiombato F.S., D-Armiento M. Differential Expression of the Components of the Plasminogen Activating System in Human Thyroid Tumor Derived Cell Lines and Papillary Carcinomas // Eur. J. Cancer. 2006. V.42.
    P.2631-2638.
  4. Shapiro R.L., Duquette J.G., Roses D. F., Nunes I., Harris M.N., Kamino H., Wilson E.L., Rifkin D.B. Induction of Primary Cutaneous Melanocytic Neoplasms in the Urokinase-Type Plasminogen Activator (uPA)-Deficient and Wild-Type Mice: Cellular Blue Nevi Invade but not Progress to Malignant Melanoma in uPA-Deficient Animals // Cancer Res. 1996. V.56. P.3597-3604.
  5. Gutierrez L.S., Schulman A., Brito-Robinson T., Noria F., Ploplis V.A., Castellino F.J. Tumor Development is Retarted in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or its Inhibitor, Plasminogen Activator Inhibitor-1 // Cancer Res. 2000. P.60. P.5839-5847.
  6. Bugge, T.H., Suh T.T., Flick M.J., Daugherty C.C., Romer J., Solberg H., Ellis V., Dano K., Degen J.L. The Receptor for Urokinase-Type Plasminogen Activator is not Essential for Mouse Development or Fertility // J. Biol. Chem. 1995. V.270. P.16886-16894.
  7. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den
    Oord J.J., Collen D., Mulligan R.C. Physiological Consequences of Loss of Plasminogen Activator Gene Function in Mice // Nature. 1994. V.368. P.419-424.
  8. Hanahan D., Weinberg R.A. The Hallmarks of Cancer // Cell. 2000. V.100. P.57-70.
  9. Blasi F., Carmeliet P. uPAR: a Versatile Signalling Orchestrator // Nat. Rev. Mol. Cell Biol. 2002. V.3. P.932-943.
  10. Bene M.C., Castoldi G., Knapp W., Rigolin G.M., Escribano L., Lemez P., Ludwig W-D., Matutes E., Orfao A., Lanza F., van-t Veer M. CD87 (Uroki-nase-Type Plasminogen Activator Receptor), Function and Pathology in Hematological
    Disorders: a Review // Leukemia. 2004. V.18. P.394-400.
  11. Irigoyen J.P., Munoz-Canoves P., Montero L., Koziczak M., Nagamine Y. The Plasminogen Activator System: Biology and Regulation // Cell. Mol. Life Sci. 1999. V.56. P.104-132.
  12. Pepper M.S. Role of Matrix Metalloproteinases and Plasminogen Activator-Plasmin System in Angiogenesis // Arterioscler. Thromb. Vasc. Biol. 2001. V.21. P.1104-1117.
  13. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. The Urokinase-Type Plasminogen Activator System in Cancer Metastasis: A Review // Int. J. Cancer. 1997. V.72. P.1-22.
  14. Lijnen H.R. Pleiotropic Functions of the Plasminogen Activator Inhibitor-1 // J. Thromb. Haemost. 2005. V.3. P.35-45.
  15. Sidenius N., Blasi F. The Urokinase Plasminogen Activator System in Cancer: Recent Advances and Implication for Prognosis and Therapy // Cancer Metastasis Rev. 2003.
    V.22. P.205-222.
  16. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L. R., Ploug M., Romer J. Plasminogen Activation and Cancer // Thromb. Haemost. 2005. V.93. P.676-681.
  17. Estreicher A., Wohlwend A., Belin D., Schleuning W.D., Vassalli J.D. Characterization of the cellular binding site for the urokinase-type plasminogen activator // J. Biol. Chem. 1989.
    V.264. P.1180-1189.
  18. Quax P.H., Grimbergen J.M., Lansink M., Bakker A.H., Blatter M.C., Belin D., van Hinsbergh V.W., Verheijen J.H. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding // Arterioscler. Thromb. Vasc. Biol. 1998. V.18.
    P.693-701.
  19. Vassalli J.D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase // J. Cell Biol. 1985. V.00. P. 86-92.
  20. Barinka C., Parry G., Callahan J., Shaw D.E., Kuo A., Bdeir K., Cines D.B., Mazar A. Lubkowski J. Structural Basis of Interaction between Urokinase-type Plasminogen Activator and its Receptor // J. Mol. Biol. 2006. V. 363. P.482-495.
  21. Castellino F.J., Ploplis V.A. Structure and Function of the Plas-minogen/Plasmin System // Thromb. Haemost. 2005. V.93. P.647-654.
  22. Stephens R.W., Pollanen J., Tapiovaara H., Leung K.C., Sim P.S., Salonen E.M., Ronne E., Beherendt N., Dano K., Vaheri A. Activation of Pro-Urokinase and Plasminogen on Human Sarcoma Cells: a Proteolytic System with Surface-Bound Reactants // J. Cell Biol. 1989.
    V.108. P.1987-1995.
  23. Estricher A., Muhlhauser J., Carpentier J.L., Orci L., Vassalli J.D. The Receptor for Urokinase Type Plasminogen Activator Polarizes the Expression of the Protease to the Leading Edge of Migrating Monocytes and Promotes Degradation of Enzyme Inhibitor Complexes // J. Cell Biol. 1990. V.111. P.783-792.
  24. Lijnen H.R. Plasmin and Matrix Metallopro-teinases in Vascular Remodeling // Thromb. Haemost. 2001. V.86. P.324-333.
  25. Giannelli G., Falk-Marzillier J., Schiraldi O., Stet-ler-Stevenson W.G., Quaranta V. Induction of Cell Migration by Matrix Metalloproteinase-2 Cleavage of Laminin-5 // Science. 1997. V.277. P.225-228.
  26. Bemis L.T., Schedin P. Reproductive State of Rat Mammary Gland Stroma Modulates Human Breast Cancer Cell Migration and Invasion // Cancer Res. 2000. V.60. P.3414-3418.
  27. Ossowski L., Aguirre-Ghiso J.A. Urokinase Receptor and Integrin Partnership: Coordination of Signaling for Cell Adhesion, Migration and Growth // Curr. Opin. Cell Biol. 2000. V.12. P.613-620.
  28. Rabbani S.A., Mazar A.P., Bernier S.M., Haq M., Bolivar I., Henkin J., Goltzman D. Structural Requirements for the Growth Factor Activity of the Amino-Terminal Domain of Urokinase // J. Biol. Chem. 1992. V.267. P.14151-14156.
  29. Kirchheimer J.C., Wojta J., Christ G., Hienert G., Binder B.R. Proliferation of Human Epidermal Tumor Cell Line Stimulated by Urokinase // FASEB J. 1987. V.1. P.125-128.
  30. Yu W., Kim J., Ossowski L. Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy // J. Cell Biol. 1997. V.137. P.767-777.
  31. Kirchheimer J.C., Wojta J., Christ G., Binder B.R. Functional Inhibition of Endogenously Produced Urokinase Decreases Cell Proliferation in a Human Melanoma Cell Line // Proc. Natl. Acad. Sci. USA. 1989. V.86. P.5424-5428.
  32. Aguirre-Ghiso J.A., Kovalski K., Ossowski L. Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling // J. Cell Biol. 1999. V.147. P.89-104.
  33. Rodenburg K.W., Kjoller L., Petersen H.H., Andreasen P.A. Binding of Urokinase-Type Plasminogen Activator-Plasminogen Activator Inhibitor-1 Complex to the Endocytosis Receptors Alpha2-Macroglobulin Receptor/Low-Density Lipoprotein Receptor-Related Protein and Very-Low-Density Lipoprotein Receptor Involves Basic Residues in the Inhibitor // Biochem. J. 1998. V.329. P.5563.
  34. Stefansson S., Muhammad S., Cheng X.F., Battey F.D., Strickland D.K., Lawrence D.A. Plasminogen Activator Inhibitor-1 Contains a Cryptic High Affinity Binding Site for the Low Density Lipoprotein Receptor-Related Protein // J. Biol. Chem. 1998. V.273. P.6358-6366.
  35. Croucher D.R., Saunders D.N., Stillfried G.E., Ranson M. A Structural Basis for Differential Cell Signalling by PAI-1 and PAI2 in Breast Cancer Cells // Biochem. J. 2007. V.408.  P.203-210. 
  36. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Pearsons J.T., Horwitz A.F. Cell Migration: Integrating Signals from Front to Back // Science. 2003. V.302. P.1704-1709.
  37. Hynes R.O. Integrins: Versatility, Modulation and Signaling in Cell Adhesion // Cell. 1992. V.69. P.11-25.
  38. Moissoglu K., Schwartz M.A. Integrin Signalling in Directed Cell Migration // Biol. Cell. 2006. V.98. P.547-555.
  39. Luo B.-H., Carman C.V., Springer T.A. Structural Basis of Integrin Regulation and Signaling // Annu. Rev. Immunol. 2007. V.25. P.619-647.
  40. Reinartz J., Schafer B., Batrla R., Klein C.E., Kramer M.D. Plasmin abrogates av b5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin // Exp. Cell Res. 1995. V.220. P.274-282.
  41. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V., Chapman H.A. Regulation of integrin function by the urokinase receptor // Science. 1996. V.273. P.1551-1555.
  42. Xue W., Mizukami I., Todd R.F. 3rd, Petty H.R. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components // Cancer Res. 1997. V.57. P.1682-1689.
  43. Xue W., Kindzelskii A.L., Todd R.F. 3rd, Petty H.R. Physical association of complement receptor type 3 and urokinase- type plasminogen acti-vator receptor in neutrophil membranes//
    J. Immunol. 1994. V.152. P. 4630-4640.
  44. Guo W., Giancotti F.G. Integrin Signaling During Tumor Progression // Nat. Rev. Mol. Cell Biol. 2004. V.5. P.816-826.
  45. Mitra S.K., Schlaepfer D.D. Integrin-Regulated FAK-Src Signaling in Normal and Cancer Cells // Curr. Opin. Cell Biol. 2006. V.18. P.516-523.
  46. Stupack D.G. The Biology of Integrins // Oncology. 2007. V.21. P.6-12.
  47. Simon D.I., Wei Y., Zhang L., Rao N.K., Xu H., Chen Z., Liu Q., Rosenberg S., Chapman H.A. Identification of a Urokinase Receptor-Integrin Interaction Site. Promiscuous Regulator of Integrin Function // J. Biol. Chem. 2000. V.275. P.10228-10234.
  48. Nguyen D.H., Catling A.D., Webb D.J., Sankovic M., Walker L.A., Somlyo A.V., Weber M.J., Gonias S.L. Myosin Light Chain Kinase Functions Downstream of Ras/ERK to Promote Migration of the Urokinase-Type Plasminogen Activator-Stimulated Cells in an Integrin-Selective Manner // J. Cell Biol. 1999. V.146. P.149-164.
  49. Nguyen, Webb D.J., Catling A.D., Song Q., Dhakephalkar A., Weber M.J., Ravichandran K.S., Gonias S.L. Urokinase-Type Plasminogen Activator Stimulates the Ras/ERK Signaling Pathway and MCF-7 Cell Migration by a Mechanism that Requires FAK, Src, and Shc: Rapid Dissociation of Grb2/Sos from Shc is Associated with the Transient Phosphorylation of ERK in Urokinase-Treated Cells // J. Biol. Chem. 2000. V.275. P.19382-19388.
  50. Nguyen D.H., Hussaini I.M., Gonias S.L. Binding of Urokinase-Type Plasminogen Activator to its Receptor in MCF7 Cells Activates Extracellular Signal-Regulated Kinase 1 and 2 which is Required for Increased Cell Motility // J. Biol. Chem. 1998. V.273. P.8502-8507.
  51. Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., de Lanerolle P., Cheresh D.A. Regulation of Cell Motility by Mitogen-Activated Protein Kinase // J. Cell Biol. 1997. V.137. P.481-492.
  52. Tang H., Kerins D.M., Hao Q., Inagami T., Vaughan D.E. The Urokinase-Type Plasminogen Activator Receptor Mediates Tyrosine Phosphorylation of Focal Adhesion Protein and Activation of Mitogen-Activated Protein Kinase in Cultured Endothelial Cells // J. Biol. Chem. 1998. V.273. P.18268-18272.
  53. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosemberg S., Chapman H.A. Identification of the Urokinase Receptor as an Adhesion Receptor for Vitronectin // J. Biol. Chem. 1994. V.269. P.32380-32388.
  54. Sidenius N., Sier C.F.M., Blasi F. Shedding and Cleavage of the Urokinase Receptor (uPAR): Identification and Characterization of uPAR Fragments in Vitro and in Vivo // FEBS Lett. 2000. V.475. P.52-56.
  55. Hoyer-Hansen G., Behrendt N., Ploug M., Dano K., Preissner K.T. The Intact Urokinase Receptor is Required for Efficient Vitronectin Binding: Receptor Cleavage Prevents Ligand Interaction // FEBS Lett. 1997. V.420. P.79-85.
  56. Waltz D.A., Chapman H.A. Reversible Cellular Adhesion to Vitronectin Linked to Urokinase Receptor occupancy // J. Biol. Chem. 1994.
    V.269. P.14746-14750.
  57. Deng G., Curriden S.A., Wang S., Rosenberg S., Loskutoff D.J. Is Plasminogen Activator Inhibitor-1 the Molecular Switch that Governs Urokinase Receptor-Mediated Cell Adhesion and Release - // J. Cell Biol. 1996. V.134. P.1563-1571.
  58. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., Fazioli F. Proteolytic Cleavage of the Urokinase Receptor Substitues for the Agonist-Induced Chemiotactic Effects // EMBO J. 1996. V.15. P.1572-1582.
  59. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E., Blasi F. The Urokinase-Sensitive Region of the Urokinase Receptor is Responsible for its Potent Chemiotactic Activity // EMBO J. 1997. V.16. P.7279-7286.
  60. Degryse B., Resnati M., Rabbani S.A., Villa A., Fazioli F., Blasi F. Src-Dependence and Pertussis-Toxin Sensitivity of Urokinase Receptor-Dependent Chemiotaxis, and Cytoskeletal Reorganization in Rat Smooth Muscle Cells Via the Urokinase Receptor // Blood. 1999. V.94. P.649-662.
  61. Resnati M., Pallavicini I., Wang J.M., Oppenheim J., Serhan C.N., Romano M., Blasi F. The Fibrinolytic Receptor for Urokinase Activates the G Protein-Coupled Chemiotactic Receptor FPRL1/LXA4R // Proc. Natl. Acad. Sci. USA. 2002. V.99. P.1359-1366.
  62. Carmeliet P., Jain R.K. Angiogenesis in Cancer and Other Diseases // Nature. 2000. V.407.
    P.249-257.
  63. Binder B.R., Mihaly J., Prager G.W. uPAR-uPA-PAI-1 Interactions and Signaling: a Vascular Biologist-s View // Thromb. Haemost. 2007. V.97. P.336-342.
  64. Plouët J., Moro F., Bertagnolli S., Coldeboeuf N., Mazarguil H., Clamens S., Bayard F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect // J. Biol. Chem. 1997. V.272. P.13390-13396.
  65. Bhuvarahamurthy V., Schroeder J., Denkert C., Kristiansen G., Schnorr D., Loening S.A., Jung K., Staack A. In Situ Gene Expression of Urokinase-Type Plasminogen Activator and its Receptor in Transitional Cell Carcinoma of the Human Bladder // Oncol. Rep. 2004. V.12. P.909-913.
  66. Pendurthi U.R., Tran T.T., Post M., Rao L.V. Proteolysis of CCN1 by Plasmin: Functional Implications // Cancer Res. 2005. V.65. P.9705-9711.
  67. Stefansson S., McMahon G.A., Petitclerc E., Lawrence D.A. Plasminogen Activator Inhibitor-1
    in Tumor Growth, Angiogenesis and Vascular Remodeling // Curr. Pharm. Des. 2003. V.9. P.1545-1564.
  68. Reich E., Berlin R.D., Herrmann H., Lepou I.H., Stanzer J.M. Activation of Plasminogen: a General Mechanism for Producing Localized Extracellular Proteolysis. In Molecular Basis of Biological Degradative Proteases // Academic Press: New York. 1978. P.155-169.
  69. Naldini L., Tamagnone L., Vigna E., Sachs M., Hartmann G., Birchmeier W., Daikuhara Y., Tsubouchi H., Blasi F., Comoglio P.M. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor // EMBO J. 1992. V.11. P.4825-4833.
  70. Dellas C., Loskutoff D.J. Historical Analysis of PAI-1 from its Discovery to its Potential Role in Cell Motility and Disease // Thromb. Haemost. 2005. V.93. P.631-640.
  71. de Bock C.E., Wang Y. Clinical Significance of Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression in Cancer // Med. Res. Rev. 2004. V.24. P.13-39.
  72. Harbeck N., Schmitt M., Paepke S., Allgayer H., Kates R.E. Tumor-Associated Proteolytic Factors uPA and PAI-1: Critical Appraisal of Their Clinical Relevance in Breast Cancer and Their Integration into Decision-Support Algorithms // Crit. Rev. Clin. Lab. Sci. 2007. V.44. P.179-201.
  73. Dass K., Ahmad A., Azmi A.S., Sarkar S.H., Sarkar F.H.Evolving Role of uPA/uPAR System in Human Cancers // Cancer Treat. Rev. 2008. V.34. P.122-136.
  74. Wang Y. The Role and Regulation of Urokinase-Type Plasminogen Activator Receptor Gene Expression in Cancer Invasion and Metastasis // Med. Res. Rev. 2001. V.21. P.146-170.
  75. Tierney M. J., Medcalf R.L. Plasminogen Activator Inhibitor Type 2 Contains mRNA Instability Elements within Exon 4 of the Coding Region. Sequence Homology to Coding Region Instability Determinants in other mRNAs // J. Biol. Chem. 2001. V.276. P.13675-13684.
  76. Ossowski L., Reich E. Antibodies to Plasminogen Activator Inhibits Human Tumor Metastasis // Cell. 1983. V.91. P.869-874.
  77. Gondi C.S., Lakka S.S., Dinh D.H., Olivero W.C., Gujrati M., Rao J.S. RNAi-Mediated Inhibition of Cathepsin B and uPAR Leads to Decreased Cell Invasion, Angiogenesis and Tumor Growth in Gli­omas // Oncogene. 2004. V.23. P.8486-8496.
  78. Gondi C.S., Lakka S.S., Dinh D.H., Olivero W.C., Gujrati M., Rao J.S. Intraperitoneal Injection of a Hairpin RNA-Expressing Plasmid Targeting Urokinase-Type Plasminogen Activator (uPA) Receptor and uPA Retards Angiogenesis and Inhibits Intracranial Tumor Growth in Nude Mice // Clin. Cancer Res. 2007. V.13. P.4051-4060.
  79. Kondraganti S., Gondi C.S., McCutcheon I., Dinh D.H., Gujrati M., Rao J.S., Olivero W.C. RNAi-Me-diated Downregulation of Urokinase Plasminogen Activator and its Receptor in Human Meningioma Cells Inhibits Tumor Invasion and Growth // Int. J. Oncol. 2006. V.28. P.1353-1360.
  80. Kunigal S., Lakka S.S., Gondi C.S., Estes N.,
    Rao J.S. RNAi-Mediated Downregulation of Urokinase Plasminogen Activator Receptor and Matrix Metalloprotease-9 in Human Breast Cancer Cells Results in Decreased Tumor Invasion, Angiogenesis and Growth // Int. J. Cancer. 2007. V.121. P.2307-2316.
  81. Gondi C.S., Kandhukuri N., Dinh D.H., Gujrati M., Rao J.S. Down-Regulation of uPAR and uPA Activates Caspase-Mediated Apoptosis and Inhibits the PI3K/AKT Pathway // Int. J. Oncol. 2007. V.31. P.19-27.
  82. Nozaki S., Endo Y., Nakahara H., Yoshizawa K., Hashiba Y., Kawashiri S., Tanaka A., Nakagawa K., Matsuoka Y., Kogo M., Yamamoto E. Inhibition of Invasion and Metastasis in Oral Cancer by Targeting Urokinase-Type Plasminogen Activator Receptor // Oral. Oncol. 2005. V.41. P.971-977.
  83. Subramanian R., Gondi C.S., Lakka S.S., Jutla A., Rao J.S. siRNA-Mediated Simultaneous Down-regulation of uPA and its Receptor Inhibits Angiogenesis and Invasiveness Triggering Apoptosis in Breast Cancer Cells // Int. J. Oncol. 2006. V.28. P.831-839.
  84. Pulukuri S.M., Gondi C.S., Lakka S.S., Jutla A., Estes N., Gujrati M., Rao J.S. RNA Interference-Directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in vivo // J. Biol. Chem. 2005. V.280. P.36529-36540.
  85. Dass C.R., Nadesapillai A.P., Robin D., Howard M.L., Fisher J.L., Zhou H., Choong P.F. Down-regulation of uPAR Confirms Link in Growth and Metastasis of Osteosarcoma // Clin. Exp. Metastasis. 2005. V.22. P.643 - 652.
  86. de Bock C.E., Lin Z., Itoh T., Morris D., Murrell G., Wang Y. Inhibition of Urokinase Receptor Gene Expression and Cell Invasion by Anti-uPAR DNAzymes in Osteosarcoma Cells // FEBS J. 2005. V.272. P.3572-3582.
  87. Pillay V., Dass C.R., Choong P.F.M. The Urokinase Plasminogen Activator Receptor as a Gene Therapy Target for Cancer // Trends Biotechnol. 2007. V.25. P.33-39.
  88. Spraggon G., Phillips C., Nowak U.K., Ponting C.P., Saunders D., Dobson C.M., et al. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator // Structure. 1995. V.3. P.681-691.
  89. Nienaber V.L., Davidson D., Edalji R., Giran-
    da V.L., Klinghofer V., Henkin J., et al. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite // Structure. 2000. V.8. P.553-563.
  90. Nienaber V., Wang J., Davidson D., Henkin J. Reengineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite // J. Biol. Chem. 2000. V.275. P.7239- 7248.
  91. Katz B.A., Mackman R., Luong C., Radika K., Martelli A., Sprengeler P.A., et al. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator // Chem. Biol. 2000. V.7. P.299-312.
  92. Spraggon G., Phillips C., Nowak U.K., Ponting C.P., Saunders D., Dobson C.M., Stuart D.I., Jones E.Y. The Crystal Structure of the Catalytic Domain of Human Urokinase-Type Plasminogen Activator // Structure. 1995. V.3. P.681-691.
  93. Graf L., Craik C.S., Patthy A., Roczniak S., Fletterick R.J., Rutter W.J. Selective Alteration of Substrate Specificity by Replacement of Aspartic Acid-189 with Lysine in the Binding Pocket of Trypsin // Biochemistry. 1987. V.26. P.2616-2623.
  94. Sturzebecher J., Markwardt F. Synthetic Inhibitors of Serine Proteinases. 17. The Effect of Benzamidine Derivatives on the Activity of Urokinase and the Reduction of Fibrinolysis // Pharmazie. 1978. V.33. P.599-602.
  95. Vassalli J.D., Belin D. Amiloride Selectively Inhibits the Urokinase-Type Plasminogen Activator // FEBS Lett. 1987. V.214. P.187-191.
  96. Yang H., Henkin J., Kim K.H., Greer J. Selective Inhibition of Urokinase by Substituted Phenyl­guanidines: Quantitative Structure-Activity Relationship Analyses // J. Med. Chem. 1990.  V.33. P.2956-2961. 
  97. Towle M.J., Lee A., Maduakor E.C., Schwartz C.E., Bridges A.J., Littlefield B.A. Inhibition of Urokinase by 4-Substituted Benzo[b]thiophene-2-Carboxamidines: an Important New Class of Selective Synthetic Urokinase Inhibitor // Cancer Res. 1993. V.53. P.2553-2559.
  98. Alonso D.F., Farias E.F., Ladeda V., Davel L., Puricelli L., Bal de Kier Joffe E. Effects of Synthetic Urokinase Inhibitors on Local Invasion and Metastasis in a Murine Mammary Tumor Model // Breast Cancer Res. Treat. 1996. V.40. P.209-223.
  99. Alonso D.F., Tejera A.M., Farias E.F., Bal de Kier Joffe E., Gomez D.E. Inhibition of Mammary Tumor Cell Adhesion, Migration, and Invasion by the Selective Synthetic Urokinase Inhibitor B428 // Anticancer Res. 1998. V.18. P.4499-4504.
  100. Rabbani S.A., Harakidas P., Davidson D.J., Henkin J., Mazar A.P.Prevention of Prostate-Cancer Metastasis in vivo by a Novel Synthetic Inhibitor of Urokinase-Type Plasminogen Activator (uPA) // Int. J. Cancer. 1995. V.63.  P.840-845. 
  101. Xing R.H., Mazar A., Henkin J., Rabbani S.A. Prevention of Breast Cancer Growth, Invasion, and Metastasis by Antiestrogen Tamoxifen Alone or in Combination with Urokinase Inhibitor B428 // Cancer Res. 1997. V.57.  P.3585-3593. 
  102. Nienaber V.L., Davidson D., Edalji R., Giranda V.L., Klinghofer V., Henkin J., Magdalinos P., Mantei R., Merrick S., Severin J.M., Smith R.A., Stewart K., Walter K., Wang J., Wendt M., Weitzberg M., Zhao X., Rockway T.Structure-Directed Discovery of Potent Non-Peptidic Inhibitors of Human Urokinase that Access a Novel Binding Subsite // Structure. 2000. V.8 P.553-563.
  103. Wendt M.D., Rockway T.W., Geyer A., McClellan W., Weitzberg M., Zhao X., Mantei R., Nienaber V.L., Stewart K., Klinghofer V., Giranda V.L. Identification of Novel Binding Interactions in the Development of Potent, Selective 2Naphthamidine Inhibitors of Urokinase. Synthesis, Structural Analysis, and SAR of N-Phenyl Amide 6-Substitution // J. Med. Chem. 2004. V.47. P.303-324.
  104. Bruncko M., McClellan W.J., Wendt M.D., Sauer D.R., Geyer A., Dalton C.R., Kaminski M.A., Weitzberg M., Gong J., Dellaria J.F., Mantei R., Zhao X., Nienaber V.L., Stewart K., Klinghofer V., Bouska J., Rockway T.W., Giranda V.L. Naphthamidine Urokinase Plasminogen Activator Inhibitors with Improved Pharmacokinetic Properties // Bioorg. Med. Chem. Lett. 2005. V.15. P.93-98.
  105. Spencer J.R., McGee D., Allen D., Katz B.A., Luong C., Sendzik M., Squires N., Mackman R.L. 4-Aminoarylguanidine and 4-Aminobenzami­dine Derivatives as Potent and Selective Urokinase-Type Plasminogen Activator Inhibitors // Bioorg. Med. Chem. Lett. 2002. V.12. P.2023-2026.
  106. Barber C.G., Dickinson R.P., Horne V.A. Selective Urokinase-Type Plasminogen Activator (uPA) Inhibitors. Part 1: 2Pyridinylguanidines // Bioorg. Med. Chem. Lett. 2002. V.12. P.181-184.
  107. Barber C.G., Dickinson R.P., Fish P.V. Selective Urokinase-Type Plasminogen Activator (uPA) Inhibitors. Part 3: 1Isoquinolinylguanidines // Bioorg. Med. Chem. Lett. 2004. V.14.
    P.3227-3230.
  108. Fish P.V., Barber C.G., Brown D.G., Butt R., Collis M.G., Dickinson R.P., Henry B.T., Horne V.A., Huggins J.P., King E., O'Gara M., McCleverty D., McIntosh F., Phillips C., Webster R. Selective Urokinase-Type Plasminogen Activator Inhi­bitors. 4. 1-(7-Sulfonamidoisoquinolinyl)Gua­nidines // J. Med. Chem. 2007. V.50.  P.2341-2351. 
  109. Frederickson M., Callaghan O., Chessari G., Congreve M., Cowan S.R., Matthews J.E., McMenamin R., Smith D. M., Vinkovi M., Wallis N.G. Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator // J. Med. Chem. 2008. V.51. P.183-186.
  110. Heynekamp J.J., Hunsaker L.A., Vander Jagt T.A., Deck L.M., Vander Jagt D.L. Uncharged Isocoumarin-Based Inhibitors of Urokinase-Type Plasminogen Activator // BMC Chem. Biol. 2006. V.6. P.1.
  111. Zhu M., Gokhale V.M., Szabo L., Munoz R.M., Baek H., Bashyam S., Hurley L.H., Von Hoff D.D., Han H. Identification of a Novel Inhibitor of Urokinase-Type Plasminogen Activator // Mol. Cancer Ther. 2007. V.6. P.1348-1356.
  112. Subasinghe N.L., Illig C., Hoffman J., Rudolph M.J., Wilson K.J., Soll R., Randle T., Green D., Lewandowski F., Zhang M., Bone R., Spurlino J., DesJarlais R., Deckman I., Molloy C.J., Manthey C., Zhou Z., Sharp C., Maguire D., Crysler C., Grasberger B. Structure-Based Design, Synthesis and SAR of a Novel Series of Thiopheneamidine Urokinase Plasminogen Activator Inhibitors // Bioorg. Med. Chem. Lett. 2001. V.11. P.1379-1382.
  113. Sperl S., Jacob U., Arroyo de Prada N., Sturzebecher J., Wilhelm O.G., Bode W., Magdolen V., Huber R., Moroder L. (4-Ami-nomethyl)Phenylguanidine Derivatives as Nonpeptidic Highly Selective Inhibitors of Human Urokinase // Proc. Natl. Acad. Sci. USA 2000. V.97. P.5113-5118.
  114. Ertongur S., Lang S., Mack B., Wosikowski K., Muehlenweg B., Gires O. Inhibition of the Invasion Capacity of Carcinoma Cells by WX-UK1, a Novel Synthetic Inhibitor of the Urokinase-Type Plasminogen Activator System // Int. J. Cancer 2004. V.110. P.815-824.
  115. Setyono-Han B., Stuerzebecher J., Schmalix W.A., Muehlenweg B., Sieuwerts A., Timmermans M., Magdolen V., Schmitt M., Klijn J.G.M., Foekens J.A. Suppression of Rat Breast Cancer Metastasis and Reduction of Primary Tumour Growth by the Small Molecule Synthetic Urokinase Inhibitor WX-UK1 // Thromb. Haemost. 2005. V.93. P.779-786.
  116. Wang C.I., Yang Q., Craik C.S. Isolation of a High Affinity Inhibitor of Urokinase-Type Plasminogen Activator by Phage Display of Ecotin // J. Biol. Chem. 1995. V.270. P.12250-12256.
  117. Yang S.Q., Craik C.S. Engineering Bidentate Macromolecular Inhibitors for Trypsin and Urokinase-Type Plasminogen Activator // J. Mol. Biol. 1998. V.279. P.1001-1011.
  118. Laboissiere M.C., Young M.M., Pinho R.G., Todd S., Fletterick R.J., Kuntz I., Craik C.S. Computer-Assisted Mutagenesis of Ecotin to Engineer its Secondary Binding Site for Urokinase Inhibition // J. Biol. Chem. 2002. V.277. P.26623-26631.
  119. Hansen M., Wind T., Blouse G.E., Christensen A., Petersen H.H., Kjelgaard S., Mathiasen L., Holtet T.L., Andreasen P.A. A Urokinase-Type Plasminogen Activator-Inhibiting Cyclic Peptide with an Unusual P2 Residue and an Extended Protease Binding Surface Demonstrates New Modalities for Enzyme Inhibition // J. Biol. Chem. 2005. V.280. P.38424-38437.
  120. Tamura S.Y., Weinhouse M.I., Roberts C.A., Goldman E.A., Masukawa K., Anderson S.M., Cohen C.R., Bradbury A.E., Bernardino V.T., Dixon S.A., Ma M.G., Nolan T.G., Brunck T.K. Synthesis and Biological Activity of Peptidyl Aldehyde Urokinase Inhibitors // Bioorg. Med. Chem. Lett. 2000. V.10. P.983-987.
  121. Kunzel S., Schweinitz A., Reissmann S., Sturzebecher J., Steinmetzer T. 4-Amidinobenzy­lamine-Based Inhibitors of Urokinase // Bioorg. Med. Chem. Lett. 2002. V.12. P.645-648.
  122. Zeslawska E., Jacob, U., Schweinitz, A., Coombs G., Bode W., Madison E. Crystals of Urokinase Type Plasminogen Activator Complexes Reveal the Binding Mode of Peptidomimetic Inhibitors // J. Mol. Biol. 2003. V. 328. P. 109-118.
  123. Schweinitz A., Steinmetzer T., Banke I.J., Arlt M.J., Sturzebecher A., Schuster O., Geissler A., Giersiefen H., Zeslawska E., Jacob U., Kruger A., Sturzebecher J. Design of Novel and Selective Inhibitors of Urokinase-Type Plasminogen Activator with Improved Pharmacokinetic Properties for Use as Antimetastatic Agents // J. Biol. Chem. 2004. V.279. P.33613-33622.
  124. Chorostowska-Wynimko J., Swiercz R., Skrzyp-czak-Jankun E., Wojtowicz A., Selman S.H., Jankun J.A Novel Form of the Plasminogen Activator Inhibitor Created by Cysteine Mutations Extends its Half-Life: Relevance to Cancer and Angiogenesis // Mol. Cancer Ther. 2003. V.2. P.19-28.
  125. Joossens J., Van der Veken P., Lambeir A.M., Augustyns K., Haemers A. Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator // J. Med. Chem. 2004. V.47. P.2411-2413.
  126. Sieńczyk M., Oleksyszyn J. Inhibition of Trypsin and Urokinase by Cbz-amino(4-Guanidinophe-nyl) Methanephosphonate Aromatic Ester Derivatives: the Influence of the Ester Group on Their Biological Activity // Bioorg. Med. Chem. Lett. 2006. V.16. P.2886-28890.
  127. Rabbani S.A., Gladu J. Urokinase Receptor Antibody can Reduce Tumor Volume and Detect the Presence of Occult Tumor Metastases in vivo // Cancer Res. 2002. V.62. P.2390-2397.
  128. Bauer T.W., Liu W., Fan F., Camp E.R., Yang A., Somcio R.J., Bucana C.D., Callahan J., Parry G.C., Evans D.B., Boyd D.D., Mazar A.P., Ellis L.M. Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met- and Insulin-Like Growth Factor-I Receptor-Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice // Cancer Res. 2005. V.65. P.7775-7781.
  129. Hu X.W., Duan H.F., Gao L.H., Pan S., Li Y.M., Xi Y., Zhao S.R., Yin L., Li J.F., Chen H.P., Wu C.T. Inhibition of Tumor Growth and Metastasis by ATF-Fc, an Engineered Antibody: Targeting Urokinase Receptor // Cancer Biol. Ther. 2008. V.7. P.651-659.
  130. Cohen R.L., Xi X.P., Crowley C.W., Lucas B.K., Levinson A.D., Shuman M.A. Effects of Urokinase Receptor Occupancy on Plasmin Generation and Proteolysis of Basement Membrane by Human Tumor Cells // Blood. 1991. V.78. P.479-487.
  131. Crowley C.W., Cohen R.L., Lucas B.K., Liu G., Shuman M.A., Levinson A.D. Prevention of Metastasis by Inhibition of the Urokinase Receptor // Proc. Natl. Acad. Sci. USA. 1993. V.90. P.5021-5025.
  132. Zhu F., Jia S., Xing G., Gao L., Zhang L., He F. cDNA Transfection of Amino-Terminal Fragment of Urokinase Efficiently Inhibits Cancer Cell Invasion and Metastasis // DNA Cell Biol. 2001. V.20. P.297-305.
  133. Mohanam S., Chandrasekar N., Yanamandra N., Khawar S., Mirza F., Dinh D.H., Olivero W.C., Rao J.S. Modulation of Invasive Properties of Human Glioblastoma Cells Stably Expressing Amino-Terminal Fragment of Urokinase-Type Plasminogen Activator // Oncogene. 2002.  V.21. P.7824-7830. 
  134. Li H., Lu H., Griscelli F., Opolon P., Sun L.Q., Ragot T., Legrand Y., Belin D., Soria J., Soria C., Perricaudet M., Yeh P. Adenovirus-Mediated Delivery of a uPA/uPAR Antagonist Suppresses Angiogenesis-Dependent Tumor Growth and Dissemination in Mice // Gene Ther. 1998.
    V.5. P.1105-1113.
  135. Li H., Griscelli F., Lindenmeyer F., Opolon P., Sun L.Q., Connault E., Soria J., Soria C., Perricaudet M., Yeh P., Lu H. Systemic Delivery of Antiangiogenic Adenovirus AdmATF Induces Liver Resistance to Metastasis and Prolongs Survival of Mice // Hum. Gene Ther. 1999.
    V.10. P.3045-3053.
  136. Kobayashi H., Gotoh J., Fujie M., Shinohara H., Moniwa N., Terao T. Inhibition of Metastasis of Lewis Lung Carcinoma by a Synthetic Peptide within Growth Factor-Like Domain of Urokinase in the Experimental and Spontaneous Metastasis Model // Int. J. Cancer. 1994. V.57. P.727-733.
  137. Burgle M., Koppitz M., Riemer C., Kessler H., Konig B., Weidle U.H., Kellermann J., Lottspeich F., Graeff H., Schmitt M., Goretzki L., Reuning U., Wilhelm O., Magdolen V. Inhibition of the Interaction of Urokinase-Type Plasminogen Activator (uPA) with its Receptor (uPAR) by Synthetic Peptides // Biol. Chem. 1997. V.378. P.231-237.
  138. Magdolen V., Burgle M., de Prada N. A., Schmiedeberg N., Riemer C., Schroeck F., Kellermann J., Degitz K., Wilhelm O.G., Schmitt M., Kessler H. Cyclo19,31[D-Cys19]-uPA19-31 is a Potent Competitive Antagonist of the Interaction of Urokinase-Type Plasminogen Activator with its Receptor (CD87) // Biol. Chem. 2001. V.382. P.1197-1205.
  139. Schmiedeberg N., Schmitt M., Rolz C., Truffault V., Sukopp M., Burgle M., Wilhelm O.G., Schmalix W., Magdolen V., Kessler H. Synthesis, Solution Structure, and Biological Evaluation of Urokinase Type Plasminogen Activator (uPA)-Derived Receptor Binding Domain Mimetics // J. Med. Chem. 2002. V.45 P.4984-4994.
  140. Sato S., Kopitz C., Schmalix W.A., Muehlenweg B., Kessler H., Schmitt M., Kruger A., Magdolen V. High-Affinity Urokinase-Derived Cyclic Peptides Inhibiting Urokinase/Urokinase Receptor-Interaction: Effects on Tumor Growth and Spread // FEBS Lett. 2002. V.528. P.212-216.
  141. Muehlenweg B., Assfalg-Machleidt I., Parrado S.G., Burgle M., Creutzburg S., Schmitt M., Auerswald E.A., Machleidt W., Magdolen V.A. Novel Type of Bifunctional Inhibitor Directed Against Proteolytic Activity and Receptor/Ligand Interaction. Cystatin with a Urokinase Receptor Binding Site // J. Biol. Chem. 2000. V.275. P.33562-33566.
  142. Krol J., Kopitz C., Kirschenhofer A., Schmitt M., Magdolen U., Kruger A., Magdolen V. Inhibition of Intraperitoneal Tumor Growth of Human Ovarian Cancer Cells by Bi- and Trifunctional Inhibitors of Tumor-Associated Proteolytic Systems // Biol. Chem. 2003. V.384. P.1097-1102.
  143. Kruger A., Soeltl R., Lutz V., Wilhelm O.G., Magdolen V., Rojo E.E., Hantzopoulos P.A., Graeff H., Gansbacher B., Schmitt M. Reduction of Breast Carcinoma Tumor Growth and Lung Colonization by Overexpression of the Soluble Urokinase-Type Plasminogen Activator Receptor (CD87) // Cancer Gene Ther. 2000. V.7. P.292-299.
  144. Lutz V., Reuning U., Kruger A., Luther T., von Steinburg S.P., Graeff H., Schmitt M., Wilhelm O.G., Magdolen V. High Level Synthesis of Recombinant Soluble Urokinase Receptor (CD87) by Ovarian Cancer Cells Reduces Intraperitoneal Tumor Growth and Spread in Nude Mice // Biol. Chem. 2001. V.382.  P.789-798. 
  145. Dewerchin M., Nuffelen A.V., Wallays G.,
    Bouche A., Moons L., Carmeliet P., Mulligan R.C., Collen D    . Generation and Characterization of Urokinase Receptor-Deficient Mice // J. Clin. Invest. 1996. V.97. P.870878.